Jenny Wong PhD

• Acted for a global biopharmaceutical company in the Australian arm of a multijurisdictional patent dispute. Acted in a patent infringement and revocation proceeding in the Federal Court in relation to patents covering pneumococcal conjugate vaccine compositions. The decision arising from this case was the first in Australia to provide detailed judicial consideration of the new support requirement for Australian patents.*
• Acted for a global biopharmaceutical company in the Australian arm of a multi-jurisdictional patent dispute. Acted in an opposition in the Australian Patent Office to oppose the grant of a patent application to a method of treating ulcerative colitis. In parallel, in the Federal Court, acted in patent infringement and revocation proceedings concerning divisional innovation patents claiming the method of treatment.*
• Advised a global originator company in relation to a patent dispute concerning a monoclonal antibody used for the treatment of various inflammatory disorders.*
• Advised a global biopharmaceutical company in relation to a patent dispute concerning a monoclonal antibody used for the treatment of breast and stomach cancers.*
• Acted for a global biopharmaceutical company in a patent infringement and rectification proceeding in relation to the company's patent covering sitagliptin, the active ingredient in the anti-diabetic medication, Januvia®.*
• Acted for a global biopharmaceutical company in a patent infringement and revocation proceeding in relation to multiple patents covering lenalidomide, the active ingredient in Revlimid® which is used to treat myeloma.*
• Acted for a global biopharmaceutical company in the Federal Court and Full Federal Court in a patent infringement and revocation proceeding regarding patents for the treatment of multiple sclerosis. The decision arising from this case established as legal precedent that evidence from multiple experts will be excluded if in substance the evidence is duplicative.*
• Acted for a global biopharmaceutical company in a patent infringement and rectification proceeding concerning patents to formulations of a GLP-1 agonist. The rectification action involved a challenge to the validity of the extension of term of the patent. The decision arising from this case confirmed that claims to a formulation are eligible for term extension.*
• Acted for an Australian pharmaceutical company in a patent infringement, revocation and rectification proceeding in relation to patents covering abuse resistant oral controlled release compositions containing oxycodone and naloxone for the treatment of pain.*
• Acted for a global biopharmaceutical company in a Federal Court appeal from a successful opposition to the grant of the company's patent relating to CRISPR technology in targeted gene editing in eukaryotic cells.*
• Acted for a global biopharmaceutical company in an appeal to the Federal Court a Patent Office opposition in relation to the company's patent relating to transgenic mouse technology.*
• Advised and acted for a global biopharmaceutical company in a patent revocation proceeding in relation to patents covering prefilled syringes.*
• Acted for an Australian mining company in a patent infringement and revocation proceeding in relation to a patent covering autonomous drill rig systems and methods.*
• Acted for a UK concrete engineering company in patent entitlement proceedings regarding patents to methods of cathodic protection of steel reinforcement in concrete structures. Also acted in costs recovery proceedings following judgment.*
• Acted for a global photovoltaic manufacturer in a patent infringement and revocation proceeding in relation to a patent covering passivation technology.*

*Denotes experience gained at previous firm.